Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

Core Insights - Metagenomi, Inc. reported financial results for Q1 2025, highlighting progress in its gene editing programs and a strong cash position to support operations through 2027 [1][10]. Business Updates - The company is focused on its lead program for hemophilia A, showing promising durability of response data with sustained FVIII activity over approximately 19 months in nonhuman primates (NHPs) [2][3]. - Emerging data from the MGX-001 program indicates higher than expected FVIII activity, with ongoing full data collection and potential for further studies [4][6]. - The NHP study demonstrated consistent FVIII activity at therapeutically relevant levels, with mean FVIII activity of 75%, 8%, and 29% in three animals during months 12-19 [7]. Financial Performance - As of March 31, 2025, the company had $226.0 million in cash, cash equivalents, and marketable securities, expected to sustain operations into 2027 [6][10]. - R&D expenses for Q1 2025 were $25.1 million, a decrease from $31.4 million in the same period of 2024 [10]. - G&A expenses were $6.8 million for Q1 2025, down from $8.8 million in Q1 2024 [11]. Platform Technology Updates - The company’s AI-driven metagenomics platform has analyzed over 7.4 billion proteins, enabling the development of a comprehensive gene editing toolbox [13]. - Recent advancements include the integration of large, therapeutically relevant genes into the human genome using novel compact CRISPR-associated transposases (CAST) systems [7]. Upcoming Events - Metagenomi plans to participate in scientific conferences in Q2 2025, presenting findings related to its AI-guided metagenomic discovery and in vivo therapeutic genome editing [9].